- Service Name
Nu.Q® Technology
- Industry
Healthcare, Diagnostics, Medical Technology, Epigenetics
- Main Value Proposition
The primary value offered is the ability to detect diseases early and monitor them effectively through simple blood tests, potentially improving patient outcomes.
- Description
Nu.Q® Technology offers innovative blood-based tests for the early detection and monitoring of diseases such as cancer and sepsis. Utilizing proprietary nucleosome quantification technology, it aims to revolutionize diagnostics by providing cost-effective and easy-to-use solutions.
- Key Features
Cost-effective routine blood tests for disease detection; Groundbreaking CE-marked diagnostic solutions; Rapid epigenetic profiling using proprietary Nucleosomics™ platform; High specificity and sensitivity in cancer detection
- Use Cases
Primary scenarios include early cancer detection, monitoring treatment efficacy, and assessing disease progression in both human and veterinary health.
- Competitive advantages
High specificity (97%) in detecting systemic cancers; Innovative liquid biopsy methods that are less invasive than traditional diagnostics; A diverse range of applications in both human and veterinary medicine
- Strengths
The main strengths include a strong focus on innovation, a robust intellectual property portfolio, and a commitment to improving patient outcomes through advanced diagnostic technologies.
- Positioning
Nu.Q® Technology positions itself as a leader in the field of epigenetics, aiming to transform diagnostics from invasive procedures to simple blood tests.
- Audience
The target users include healthcare professionals, researchers in oncology and veterinary medicine, and pharmaceutical companies involved in drug development.
- CTA
Contact Us
- Tags
early diagnosis
blood tests
epigenetics
cancer detection
- Tagline
Brighter tomorrow.
- Tone of Voice
Innovative, determined, compassionate
- Differentiation
Nu.Q® Technology is unique in its focus on epigenetic changes in nucleosomes as biomarkers, which allows for early detection of diseases that are often diagnosed at later stages.
- Brand Positioning
VolitionRx is identified as a forward-thinking company dedicated to advancing the science of epigenetics and improving diagnostic processes.
- Founded
2010-01-01
- Founders
Andreas Ladurner
Martin Faulkes